Catherine Diefenbach, MD, from NYU Langone, discusses cutting-edge advancements in non-Hodgkin lymphoma therapies. She highlights promising novel combinations for diffuse large B-cell lymphoma and mantle cell lymphoma, including a triplet regimen with acalabrutinib. The use of bispecific antibodies is also explored, showcasing their therapeutic potential. Diefenbach shares insights from the recent ASH meeting on CAR T-cell therapy advancements, emphasizing new treatments that enhance patient accessibility and response rates.